Take A Look At Our Newsletter and Sign Up Today!! VHGI,KATX,SNSR,KRNY,CGEN,AFFX

(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: VHGI) VirtualHealth Technologies, Inc., (PINKSHEETS: KATX) KAT Exploration Inc., (OTCBB: SNSR) Sanswire Corp., (NASDAQ: KRNY) Kearny Financial, (NASDAQ: CGEN) Compugen Ltd., (NASDAQ: AFFX) Affymetrix, Inc.

www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: VHGI - VirtualHealth Technologies, Inc.) LATEST NEWS!! VHGI: VHGI Gold Releases Treasure Gulch and Zero Mines Initial Technical Analysis of $50,000,000 Estimated Gold Reserves LEXINGTON, Ky., Dec 22, 2009 -- Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI) through its wholly owned subsidiary VHGI Gold, today released initial analysis of technical data received from the consultants hired to evaluate and formulate its development plan at the Treasure Gulch and Zero Mining properties in Prescott, Arizona. Recoverable estimates are approximately 45,000 ounces of Gold between the 2 claims, with a combined extractable value of approximately $50,000,000 using valuations of $1200.00 per ounce of gold. Initial production costs are budgeted at approximately $200.00 per ounce.

VHGI intends to release updates concerning their gold development plan including financial feasibility studies for this and other projects under consideration after scheduled ore sampling, laboratory testing and continued project analysis. Current historical data for this property can be viewed in our last 8K filing.

Property Overview Both vein systems are strong and continuations over hundreds of feet. At surfaces on the Treasure Gulch property are approximately 5000 tons of ore, amenable to low cost surface extraction. Additional reserves are available with depth, but no doubt only by underground development. The surface block will average approximately .7 to .9 ounces per ton (opt) Au, but with mine dilution a 0.6 opt Au can be expected. As identified by underground sampling, ore with a much higher tenor is clearly to be expected from any future production; nevertheless, the entire ore reserve block has been assigned a conservative average of 0.65 oz/ton Au after dilution. Still, evidence clearly suggests a grade far in excess of 1.0 oz/ton Au within the deeper workings.

Treasure Gulch Reserves Calculations The ore reserve block at the Treasure Gulch mine averages 8 feet wide, has a minimum vertical dimension of 100 feet and a strike length of 500 feet. It is known that the vein system extends at least 200 feet; nevertheless, for reserve calculations a 100 foot cutoff is assigned. A lower block is considered as only possible and therefore not considered in any valuation. The total tonnage for a combined proven/probable ore reserve is then: 8' x 100' x 500'/ 12 cu.ft/ton = 33,330 tons.

A weighted average grade was calculated and arbitrarily reduced to approach the average grade of the surface oxidized block at approximately 0.65 oz/ton Au, with silver values ignored. The result is a total tonnage of 33,330 tons, yielding 21,664 oz of Au.

Zero Mines Reserves Calculations The Zero vein has considerable known strike length, but due to insufficient sampling, a portion of both the east and west extension have been eliminated for any calculations, and a deeper possible block has also been ignored for reasons of conservatively. The end result is a block summarized from detailed calculations to be as follows: 5' x 100' x1000'/12 = 41,660 tons of ore. As with the Treasure Gulch Mine, a detailed calculation for weighted average ore tenor was made with the results being 0.58 oz/ton Au yielding 24,163 oz Au.

Summary At $1200/ oz Au, the total reserve would result in a calculated gross recoverable value of 45,827 oz Au x $1200/ oz = $54,992,400. Assuming a recovery rate of 92% (typical for a hard rock recovery operation) the extractable value would be $50,593,008. No account here is made to predict the cost of production but a reasonable estimation would be $100 per ton of processed ore or approximately $200/ ounce Au. One should also not discount the secondary ore bodies that are believed to be a depth and east and west of strike.

For more information please consult the company's 8K filing. Information can also be obtained at http://www.virtualhealthtechnologies.com or http://www.vhgigold.com , or by calling shareholder relations at 859-514-6982.

About VHGI and VHGI Gold VHGI is a diverse company with assets and interests focusing on opportunities within the Healthcare Technology Industry and Precious Metals / Energy Resources Markets. VHGI Gold, a wholly owned subsidiary of VHGI has recently initiated steps to leverage the company's operating history and corporate resources within the Gold Mining, Precious Metals and Energy Resources Markets. Although Gold is selling at 25 year high prices and Oil & Gas continue to be trading at significant premiums, global economic events have created significant opportunities within these markets. VHGI intends to pursue these opportunities through Lease-Purchase opportunities, Acquisitions and Joint Ventures for the goal of enhanced shareholder value.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: KATX - KAT Exploration Inc.) LATEST NEWS!! Kat Exploration Inc: Kat Exploration Inc. Announces Option Agreement to Purchase 100% of the "Twi-Lite" High Grade Gold Property Dec, Dec 22, 2009 -- MOUNT PEARL, Newfoundland, Kat Exploration Inc. ("Kat") (Pink Sheets: KATX) www.katexploration.com The company is pleased to announce that further to its news release on December 9, 2009 of a LOI it has now completed the signing of an option agreement with Steve Courtney a senior prospector, for the Twi-Lite gold property consisting of 48 claims, located 14 kilometers southwest of Grandfalls -Winsor Newfoundland.

Kat as agreed to acquire a100 percent interest in the Twi-Lite property during a three-year period in consideration of total cash payments of $144,000, which includes a payment of $18,000 on signing $30,000 on first anniversary of the option agreement, $46,000 second anniversary and $50,000 third anniversary. No shares of Kat Exploration is involved in the deal.

Kat Exploration will be the operator of the project during the option period. "We are very pleased to have the Twi-Lite property as part of our gold portfolio. It provides us with greater opportunity to expand our position as a real gold player. The companyaEUR(TM)s field crews will now build on past work and examine high priority targets which offer excellent potential for the discovery of new gold mineralization.aEUR aEURoeOur management team believes that Twi-Lite is a highly prospective property based on strong exploration results to date, its favorable geology and strategic location,aEUR said Ken Stead, President and CEO of Kat Exploration. Some results to date: The Discovery Prospect: Zone of quartz veining and associated silicification, high of 202 g/t Au (Visible Gold).

The Spring Pit prospect: bedded pyrite/mafic fault gouge (high of 14.9 g/t).

The 320 Vein: zone of quartz veining and quartz breccias (high of 16.6 g/t).

The PaddyaEUR(TM)s Pitt prospect: silicified and brecciated siltstone (high of 23.80 g/t).

Information pertaining to the Twi-Lite property will be posted to the website in the very near future.

About Kat Exploration Kats ExplorationaEUR(TM)s principal objective is to locate, stake, prove up and sell mineral properties throughout the province of Newfoundland. It is the CompanyaEUR(TM)s objective to take advantage of increased activity to generate joint venture clients, and sales of our existing and yet to be acquired properties.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: SNSR - Sanswire Corp.) LATEST NEWS!! Video of Sanswire's STS-111 Unmanned Aerial Vehicle (UAV) Demonstration Available on www.Sanswire.com FORT LAUDERDALE, FL, Dec 23, 2009 -- Sanswire Corp. (OTCBB: SNSR) today announced that video footage of the STS-111 UAV in flight testing has been released to their website www.Sanswire.com. The flight video highlights a recent demonstration of the company's lighter-than-air STS-111 Unmanned Aerial Vehicle (UAV). The video was shot during a private event held on December 18, 2009, in Stuttgart, Germany.

Captain David Christian, CEO of Sanswire, said, "The video clearly shows off the STS-111 to great advantage. Viewers get a real sense of how the unique segmented design functions, how maneuverable the aircraft is, and how this platform can provide intelligence and surveillance support for military and Homeland Security missions." The STS-111 UAV is designed to rapidly unfold from its standard-size crate and launched with minimal ground infrastructure and crew. The STS-111 can carry various payloads of intelligence, surveillance, reconnaissance and communications equipment, and provide operational line of sight of up to 170-miles. The airship is capable of fulfilling a range of mission profiles at mid altitudes, performing both persistent loitering and racetrack operations nonstop for an estimated two and a half days.

To view the video and information on the STS-111 UAV please visit www.Sanswire.com About Sanswire-TAO Corp.

Sanswire-TAO exclusively owns and markets all the technology and intellectual property associated with TAO's lighter-than-air (LTA) unmanned aerial vehicles (UAV), including the Stratellite(TM) high-altitude airships, the SAS-51 low-altitude airships, the mid-altitude STS-111 airship, and the PADDS (Precision Air Drop Delivery System) in the US, Canada and Mexico. Sanswire-TAO Corp. is jointly owned by TAO Technologies GmbH and Sanswire Corp. For more information, visit www.sanswire-tao.com.

About Sanswire Corp.

Sanswire Corp. (OTCBB: SNSR) is a developer of integrated aerospace communications products and services. The company specializes in the design and construction of autonomous, lighter-than-air UAVs (Unmanned Aerial Vehicles) capable of carrying payloads that provide persistent security solutions at low, mid, and high altitudes. Sanswire's airships and auxiliary products are designed for use by commercial and government-related entities that require real-time intelligence, surveillance, and reconnaissance support for homeland defense, maritime, and border missions. The company's long-term objective to develop and deliver state-of-the-art airship technology that provides surveillance sensor suites and other advanced wireless broadband capabilities to the broader commercial markets.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: KRNY - Kearny Financial) LATEST NEWS!! Kearny Financial Corp. Announces Cash Dividend FAIRFIELD, NJ, Dec 23, 2009 -- Kearny Financial Corp. (NASDAQ: KRNY) (the "Company") announced today that the Company's Board of Directors has declared a quarterly cash dividend of $.05 per share to stockholders of record as of January 4, 2010 payable on January 22, 2010. The Company is the majority-owned subsidiary of Kearny MHC, a federally chartered mutual holding company, which owns 73.66% of the Company's outstanding shares.

Kearny Financial Corp. is the holding company for Kearny Federal Savings Bank, which operates from its administrative headquarters building in Fairfield, New Jersey, and 27 retail branch offices located in Bergen, Hudson, Passaic, Morris, Middlesex, Essex, Union and Ocean Counties, New Jersey. At September 30, 2009, Kearny Financial Corp. had total assets, loans, deposits and stockholders' equity of $2.16 billion, $1.05 billion, $1.46 billion and $482.0 million, respectively. Shares of Kearny Financial Corp. trade on the Nasdaq Global Select Market under the symbol "KRNY." ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: CGEN - Compugen Ltd.) LATEST NEWS!! Compugen Announces "Discovery on Demand" Therapeutic Peptide Collaboration with Pfizer TEL AVIV, Israel, Dec 23, 2009 -- Compugen Ltd. (NASDAQ:CGEN) announced today that it has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates for three drug targets of interest to Pfizer. The discovery process, which will be based on various Compugen discovery platforms and funded by Pfizer, is expected to take a few months, following which the predicted molecules will be synthesized and delivered to Pfizer. Following an evaluation period, Pfizer will have the right to exercise options for worldwide exclusive milestone and royalty bearing licenses to develop and commercialize the selected product candidates or further optimize them to obtain final potent, selective product candidates with favorable pharmacokinetic properties.

"Although use of our various discovery platforms is now providing us with a growing inventory of novel drug and target candidates for further development and licensing, the most unique aspect of our capabilities is the ability to systematically and within a short timeframe provide, what we call, discovery on demand product candidates for selected areas of interest to our partners," Dr. Anat Cohen-Dayag, president and co-CEO of Compugen said. "We are extremely pleased to be entering into this multi-target collaboration with Pfizer, and we look forward to entering into similar agreements with additional pharmaceutical and biopharmaceutical companies." About Compugen's Discovery Platforms During the past few years, Compugen has designed, developed, validated and disclosed ten product candidate discovery platforms directed at various important areas of drug and diagnostic discovery. The development of this diverse range of discovery platforms in such a short period of time was possible only due to Compugen's commitment since 1997 to understand deeply the science underlying various important biological phenomena. Utilizing this continuously growing base of scientific understanding, Compugen has created, and continues to create, predictive models, algorithms and other computational biology methodologies that provide a unique and rich infrastructure for the design of systematic platforms for the predictive discovery of novel drug, target and biomarker candidates. Most of Compugen's ten discovery platforms developed to date are based on a process of in silico prediction and selection, followed by synthesis and experimental validation. The initial in silico predictions usually involve a large number -- often in the thousands or more - of possible candidates, with the selection step resulting in a very small subset -- usually dozens of molecules or less - which are predicted to have the highest probability of success. These molecules are then prioritized, synthesized, and experimentally validated. Among the Compugen platforms developed to date based on this prediction-selection-validation process are platforms designed for the discovery of therapeutic proteins and peptides, targets for monoclonal antibodies, and both molecular and genetic biomarkers.

One of the key Compugen platforms to be utilized in the Pfizer collaboration announced today was recently developed, and has not yet been publicly disclosed. This undisclosed platform is based on a process which is different from the prediction-selection-validation process underlying most of Compugen's previously announced discovery platforms as described above. In this second process, Compugen's multidisciplinary scientific team uses its understandings of certain basic biological phenomena and advanced computational biology capabilities to "design", in silico, molecules that should meet the specific requirements needed for them to become optimal therapeutic candidates for the relevant target. As with all of our in silico platforms, these predicted molecular sequences are then synthesized and experimentally validated. This prediction-design-validation approach is also the process utilized by Compugen's previously disclosed Disease Associated Conformations ("DAC") Blockers Platform, but in this case employing different discovery principles and models.

About Compugen Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. The resulting product candidates are then validated through in vitro and in vivo experimental studies and out-licensed for further development and commercialization under various forms of revenue sharing agreements. Compugen's collaborations to date include Bayer Schering Pharma, Biosite, Medarex, Inc., Merck & Co., Inc., Merck Serono, Ortho-Clinical Diagnostics (a Johnson & Johnson company), Pfizer, Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate, Evogene Ltd. www.evogene.com (TASE:EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: AFFX - Affymetrix, Inc.) LATEST NEWS!! Affymetrix to Present at the 28th Annual J.P. Morgan Healthcare Conference SANTA CLARA, Calif., Dec 23, 2009 -- Affymetrix, Inc. (NASDAQ: AFFX) today announced that Kevin M. King, President and Chief Executive Officer, will provide a company overview at the J.P. Morgan Healthcare Conference on January 14 in San Francisco. A live webcast of the presentation will take place at 9:00 A.M. PT.

To access the live and archived webcasts, please visit www.affymetrix.com and click on the "Webcast Archive" link in the "Investors" section. An archived webcast of the presentation will be available for 30 days.

About Affymetrix Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and not-for-profit research institutes. More than 1,800 systems have been shipped around the world and more than 20,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To Homepage ]

| More

The World's Largest Communications And Technology Community

Technology Marketing Corporation,
800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-866-3326
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.

» About » Contact » Advertise